Clinical trial
Zalutumumab in Patients With Non-curable Head and Neck Cancer
NCT00382031 · Genmab, Industry · Completed
Key facts
| NCT number | NCT00382031 |
|---|---|
| Title | Zalutumumab in Patients With Non-curable Head and Neck Cancer |
| Official title | An Open-Labeled Randomized Parallel Group Trial of Zalutumumab, a Human Monoclonal Anti-EGFr Antibody, in Combination With Best Supportive Care (BSC) vs BSC, in Pts With Non-Curable SCCHN Who Have Failed Standard Platinum-Based Chemotherapy |
| Lead sponsor | Genmab, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer, Squamous Cell Cancer |
| Intervention type | Drug, Other |
| Interventions | Zalutumumab, Control |
| Enrollment | 286 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Aug 1, 2011 |
| First posted | Sep 28, 2006 |
| Last update posted | Oct 15, 2013 |
| Countries | Belgium, Brazil, Canada, Estonia, France, Hungary, Lithuania, Poland, Russia, Serbia, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: